Faraday Pharmaceuticals
Faraday Pharmaceuticals is focused on developing innovative treatments for acute conditions such as myocardial infarction and chronic diseases like cancer. Their mission is to solve the reperfusion problem by investigating sodium iodide as a novel approach for addressing ischemia-reperfusion injury (IRI). They are developing FDY-5301, a product aimed at reducing cardiac damage and heart failure following myocardial infarctions, currently in Phase 3 clinical trials. The company was founded by Dr. Mark Roth of the Fred Hutchinson Cancer Center and is committed to harnessing the properties of iodide to neutralize deleterious hydrogen peroxide during ischemia-reperfusion injury.
Industries
Nr. of Employees
small (1-50)
Faraday Pharmaceuticals
Seattle, Washington, United States, North America
Products
FDY-5301
Investigational sodium‑iodide therapeutic candidate developed to reduce ischemia–reperfusion injury during myocardial infarction by neutralizing deleterious hydrogen peroxide; under evaluation in a Phase 3 pivotal trial.
FDY-5301
Investigational sodium‑iodide therapeutic candidate developed to reduce ischemia–reperfusion injury during myocardial infarction by neutralizing deleterious hydrogen peroxide; under evaluation in a Phase 3 pivotal trial.
Services
Clinical development of investigational therapeutics
End-to-end clinical development services for investigational acute-care therapeutics, including trial design, site operations, enrollment, and data collection for pivotal studies.
Scientific communication and event engagement
Organization and participation in webinars, satellite symposia, and conference presentations to disseminate clinical and scientific findings.
Clinical development of investigational therapeutics
End-to-end clinical development services for investigational acute-care therapeutics, including trial design, site operations, enrollment, and data collection for pivotal studies.
Scientific communication and event engagement
Organization and participation in webinars, satellite symposia, and conference presentations to disseminate clinical and scientific findings.
Expertise Areas
- Clinical trial management (Phase 2–3)
- Acute cardiovascular therapeutics (ischemia–reperfusion injury)
- Translational preclinical pharmacology
- Regulatory strategy and FDA engagement
Key Technologies
- Pivotal randomized clinical trial execution
- Preclinical ischemia–reperfusion animal models
- Iodide-based therapeutic mechanism (hydrogen peroxide neutralization)
- Acute‑use formulation development